Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Raw Materials (2020 - 2022)

Cardiol Therapeutics filings provide 3 years of Raw Materials readings, the most recent being $259966.1 for Q3 2022.

  • On a quarterly basis, Raw Materials fell 3.48% to $259966.1 in Q3 2022 year-over-year; TTM through Sep 2022 was $259966.1, a 3.48% decrease, with the full-year FY2021 number at $268981.4, up 3.43% from a year prior.
  • Raw Materials hit $259966.1 in Q3 2022 for Cardiol Therapeutics, down from $265931.5 in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $275827.2 in Q2 2021 to a low of $259966.1 in Q3 2022.
  • Median Raw Materials over the past 3 years was $267672.4 (2022), compared with a mean of $266827.8.
  • Biggest five-year swings in Raw Materials: grew 3.43% in 2021 and later decreased 3.59% in 2022.
  • Cardiol Therapeutics' Raw Materials stood at $260070.7 in 2020, then grew by 3.43% to $268981.4 in 2021, then fell by 3.35% to $259966.1 in 2022.
  • The last three reported values for Raw Materials were $259966.1 (Q3 2022), $265931.5 (Q2 2022), and $267672.4 (Q1 2022) per Business Quant data.